Unopposed oestrogen and survival of breast cancer

Breast

Volumn 7, Issue 2, 1998, Pages 66-71

  Badwe, R A ^a   Bhansali, M S ^a   Vaidya, J S ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; BODY FAT; BODY WEIGHT; BREAST CANCER; CANCER SURVIVAL; ESTROGEN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENOPAUSE; MENSTRUAL CYCLE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0031745486     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(98)90058-3     Document Type: Review

References (98)

1. Beatson C T. On treatment of inoperable cases of carcinoma of the mamma suggestions for new methods of treatment with illustrative cases. Lancet 1896; 2: 104-107.
2. Meuller C B, Ames F, Anderson G D. Breast cancer in 3558 women: age as a significant prognostic determinant in the rate of dying and causes of death. Surgery 1978; 83: 123-132.
3. Ratajczak H V, Sothern R B, Hrushesky W J M. Estrous influence on surgical cure of mouse breast cancer. J Exp Med 1988; 168: 73-83.
4. Hrushesky W J M et al. Menstrual influence on surgical cure for breast cancer. Lancet 1989; 2: 949-952.
5. Gelber R, Goldhirsch A. Menstrual effect on surgical cure of breast cancer. Lancet 1989; 2: 1344.
6. Powles T J, Jones S E, Ashley S, Tidy A. Menstrual effect on surgical cure of breast cancer. Lancet 1989; 2: 1343-1344.
7. Ville Y, Larsy S, Spyratos F et al. Menstrual status and breast cancer surgery. Breast Cancer Res Treat 1990; 16: 119.
8. Badwe R A, Gregory W M, Chaudary M A et al. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991; 337: 1261-1264.
9. Veronesi U, Luini a, Mariani L et al. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 343: 1544-1546.
10. Badwe R A, Havaldar R. Timing of surgery in breast cancer (letter). Lancet 1994; 344: 404.
11. Caleffi M, Fentiman I S. Factors at presentation influencing the prognosis in breast cancer. Eur J Cancer Clin Oncol 1989; 25: 51-56.
12. Langlands A O, Pocock S J, Kerr G R, Gore S M. Longterm survival of patients with breast cancer; a study of the curability of the disease. BMJ 1979; 2: 1247-1251.
13. Yen S. Physiology of menstrual cycle. In: Yen S, Jaffe R B, eds. Reproductive endocrinology. Philadelphia: WB Saunders, 1986: 126-151.
14. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Oxford: Oxford University Press, 1990.
15. Grodin J M, Siiteri P K, MacDonald P C. source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207-214.
16. Trichopoulos D, Brown J, MacMahon B. Urine estrogens and breast cancer risk factors among post-menopausal women. Int J Surg 1987; 40: 721-725.
17. Ville Y, Briere M, Lasry S et al. Timing of surgery in breast cancer (letter). Lancet 1991; 337: 1604-1605.
18. Tretli S, Haldorson T, Ottestad L. The effect of premorbid height and weight on survival of breast cancer patients. Br J Cancar 1990; 62: 299-303.
19. Halvorsen K T, Burdick E, Colditz G A et al Reporting standards in meta-analysis. In: Mosteller F, Bailer J C, eds. Boston: Medical uses of statistics. N Engl J Med Books, 1992: 413-426.
20. Von Minckwitz G, Kaufman M et al Timing of surgery during the menstrual cycle in operable breast cancer (abstr). Lancet meeting on challenge of breast cancer, April 1994: 77.
21. Engele L, Yaunalksne I, Berzins J, Nikitina M. Timing of radical mastectomy, immune parameters and 5 year survival in premenopausal breast cancer patients (abst). Eur J Cancer 1994; 30A(S2): S70-S75.
22. Callies R, Klemt W, Regidor P, Hoyme W. Timing of surgery in the menstrual cycle and operable breast cancer. Arch Gynecol Obstet 1993; 254: 787-789.
23. Donegan W L, Shah D, Wood W C. Prognosis of patients with breast cancer related to timing of surgery. Arch Surg 1993; 128: 309-313.
24. Sohrabi A, Sandoz J, Spratt J S, Polk H C. Recurrence of breast cancer obesity, tumour size and axillary lymph node metastases. JAMA 1980; 244: 264-265.
25. Bastarachea J, Hortobagyi G N, Smith M S, Kans W C, Buzdar A U. Obesity as an adverse prognostic factors for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994; 120: 18-25.
26. Adami H O, Malker B, Holmberg L et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315: 559-563.
27. Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer 1986; 57: 2217-2221.
28. Rutquist L E, Wallgren A. The influence of age on outcome in breast cancer. Acta Radiol Oncol 1983; 22: 289-294.
29. Kleinfeld G, Haagensen C D, Cooley E. Age and menstrual status as prognostic factors in carcinoma breast. Ann Surg 1963; 157: 600-605.
30. Blarney R W. Premenopausal breast cancer: update on management. Medical Dialogue 1992; 355: 1-2.
31. Tough I C K. The menopause and prognosis in breast cancer. J R Coll Surg Edinb 1969; 14: 337-339.
32. Melnik U, Slater P E, Katz L, Davies A M. Breast cancer in Israel 1960-75, effect of age and origin on survival. Eur J Cancer 1980; 16: 1017-1023.
33. Palmer M K, Lythgoe J P, Smith A. Prognostic factors in breast cancer. Br J Surg 1982; 69: 697-698.
34. Gloeckler R, Pollack E S, Young J L. Cancer patient survival: SEER program 1973-79. J Natl Cancer Inst 1983; 70: 693-707.
35. Nemoto T, Vana J, Bedwani R N et al. Management and survival of female breast cancer: results of national survey by American College of Surgeons. Cancer 1980; 45: 2917-2924.
36. Richards G E. Mammary cancer: the place of surgery and radiotherapy in its management. Br J Radiol 1948; 21: 109-127.
37. Nikkanen V, Linna M, Toikanen S. Treatment results in mammary cancer stage I-IV. Acta Radiol Oncol Radit Phys Biol 1981; 20: 9-18.
38. Crowe J P, Gordon N H, Shenk R R et al. Age does not predict breast cancer outcome. Arch Surg 1994; 129: 483-488.
39. Bonnier P, Romain S, Charpin C et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995; 62: 138-144.
40. Albain K S, Allred D C, Clark G M. Breast cancer outcome and predictors of outcome: are there age differentials? Monogr Natl Cancer Inst 1994; 16: 35-42.
41. Solin J S, Fowble B, Schultz D J, Goodman R L. Age as a prognostic factor for patients treated with definitive irradiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989; 16: 373-381.
42. Sant M, Gatta G, Micheli A et al. Survival and age at diagnosis of breast cancer in a population based cancer registry. Eur J Cancer 1991; 27: 981-984.
43. Matthews R H, McNeese M D, Montague E D, Oswald M J. Prognostic implication of age in breast cancer patients treated with tumorectomy and irradiation or with mastectomy. Int J Radiat Oncol Biol Phys 1988; 14: 659-663.
44. Badwe R A, Fentiman I S, Richards M A et al. Surgical procedures, menstrual cycle phase and prognosis in operable breast cancer. Lancet 1991; 338: 815-816.
45. Senie R T, Rosen P P, Rhodes P, Lesser M L Timing of breast cancer excision during the menstrual cycle influences duration of disease free survival. Ann Intern Med 1991; 115: 337-342.
46. Sainsbury R, Jones M, Parker D et al. Timing of surgery in breast cancer (letter). Lancet 1991; 338: 392.
47. Goldhirsch A, Gelber R, Forbes J et al. Timing of surgery in breast cancer (letter). Lancet 1991; 338: 691-692.
48. Low S C, Galea M H, Blarney R W. Timing of breast cancer surgery (letter). Lancet 1991; 338: 691.
49. Powles T J, Ashley S E, Nash A G et al. Timing of surgery in breast cancer (letter). Lancet 1991; 337: 1604.
50. Rageth J C et al. Timing of breast cancer surgery within the menstrual cycle: influence of lymph node involvement, receptor status, postoperative metastatic spread and local recurrence. Ann Oncol 1991; 2: 269-272.
51. Gnant M F X, Seifert M, Jakesz R et al. Breast cancer and timing of surgery during menstrual cycle. A 5-yr analysis of 385 premenopausal women. Int J Cancer 1992; 52: 707-712.
52. Stewart H. Does the menstrual timing of surgery in breast cancer affect survival? Results from other centres. Paper presented at the symposium on the treatment of breast cancer in premenopausal women, 14-15 August 1991, King's College, Cambridge.
53. Nathan B, Bates T, Anbazhagan R, Norman A R. Timing of surgery in relation to menstrual cycle and survival in premenopausal women with breast cancer. Br J Surg 1993; 80: 43.
54. Sigurdsson H et al. Timing of surgery in the menstrual cycle does not appear to be a significant determinant of outcome in primary breast cancer. Doctoral dissertation, Lund University, 1992: 1-10.
55. Saad Z, Bramwell V, Duff J et al. Timing of surgery in relation to menstrual phase and its impact on survival in early breast cancer. Br J Surg 1994; 81: 217-220.
56. Marques L A, Franco E L. Association between timing of surgery during the menstrual cycle and prognosis in premenopausal breast cancer. Int J Cancer 1993; 53: 707-708.
57. Spratt J S, Zirnheld J, Yancey J M. BCDDP data can determine whether prognosis of breast cancer is affected by timing of surgery during the menstrual cycle. J Surg Oncol 1993; 53: 4-9.
58. Corder A P, Cross M, Julions S A et al. Timing of surgery and breast cancer. Postgrad J Med 1994; 68: 137-139.
59. Jaeger J. Timing of surgery during the menstrual cycle does not influence survival in breast cancer. Ann Oncol 1994; 5: 24-28.
60. Wobbes T, Thomas C M, Segers M F et al. The phase of menstrual cycle has no influence on the disease free survival of patients with mammary cancer. Br J Cancer 1994; 69: 599-600.
61. Stonelake P S, Powell J, Warwick J et al. Timing of surgery during the menstrual cycle in operable breast cancer. Br J Cancer 1993; 67: SXX: 16.
62. Kroman N, Hojgaard A, Andersen K W et al. Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Eur J Surg Oncol 1994; 20: 430-435.
63. Von-Minckwitz G, Kaufmann M, Dobberstein S, Grischke E M, Diel I J. Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenpausal breast cancer patients. The Breast 1995; 4: 29-32.
64. D'eredita G, De-Leo-G, Punzo C et al. Timing of breast cancer surgery during menstrual cycle. A 10 year analysis of 133 premenopausal women. The Breast 1995; 4: 25-28.
65. Holli K, Isola J, Hakama M. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient: fact of fallacy. Br J Cancer 1995; 71: 124-127.
66. Kurebayashi J, Sonoo H, Shimozuma K. Timing of surgery in relation to the menstrual cycle and its influence on the survival of Japanese women with operable breast cancer. Surg Today 1995; 25: 519-524.
67. Donegan W L, Hartz A J, Rimm A A. The association of body weight and recurrent cancer of the breast. Cancer 1978; 41: 1590-1594.
68. Senie R T, Rosen P P, Rhodes P et al. Obesity at diagnosis of breast cancer influences duration of disease free survival. Ann Intern Med 1992; 116: 26-32.
69. Vatten L J, Foss O P, Kvinnsland S. Overall survival of breast cancer in relation to preclinically determined total serum cholesterol, body mass index, height: a population based study. Eur J Cancer 1991; 27: 641-646.
70. Tartter P I, Papatestas A E, Ioannovich J et al. Cholesterol and obesity as prognostic factors in breast cancer. Cancer 1981; 47: 2222-2227.
71. Kyogoku S, Hirohata T, Takeshita S et al. Survival of breast cancer patients and body size indicators. Int J Cancer 1990; 46: 824-831.
72. Coates R J, Clarke W S, Eley J W et al. Race, nutritional status and survival from breast cancer. J Natl Cancer Inst 1990; 82: 1684-1692.
73. Newman S C, Miller A B, Howe G R. A study of the effect of weight and dietary fat on breast cancer survival. Am J Epidemiol 1986; 123: 767-774.
74. Zumoff B, Gorzynski G, Katz J L et al. Nonobesity at the time of mastectomy is highly predictive of 10 yr disease free survival in women with breast cancer. Anticancer Res 1982; 2: 59-62.
75. Boyd N F, Campbell J E, Germanson T et al. Body weight and prognosis in breast cancer. J Natl Cancer Inst 1981; 67: 785-789.
76. Lees A W, Jenkins H J, May C L et al. Risk factors and 10 year breast cancer survival in Northern Alberta. Breast Cancer Res Treat 1989; 13: 143-151.
77. Mohle-Boetani J C, Grosser S, Whittemore A S et al. Body size, reproductive factors and breast cancer survival. Pre Med 1988; 17:634-642.
78. Hebert J R, Augustine A, Barone J et al. Weight, Height and body mass index in the prognosis of breast cancer: early results of prospective study. Int J Cancer 1988; 42: 315-318.
79. Eberlein T, Simon R, Fisher S, Lippman M E. Height, weight and risk of breast cancer relapse. Breast Cancer Res Treat 1985; 5: 81-86.
80. Katoh A, Watzlaf V J M, D'Amico F. An examination of obesity and breast cancer survival in postmenopausal women. Br J Cancer 1994; 70: 928-933.
81. Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 1991, 49: 526-530.
82. Jain M, Miller A B. Pre-morbid body size and the prognosis of breast cancer. Int J Cancer 1994; 59: 363-368.
83. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, vol 1: Worldwide evidence 1985-1990. Oxford: Oxford University Press, 1990: 12-18.
84. Rochfort H, Augereau P, Briozzo P et al. Structure, function, regulation and clinical significance of the 52K pro-cathepsin-D secretion by breast cancer cells. Biochemie 1988; 70: 943-949.
85. Duffy M J, Reilly D, O'Sullivan C et al. uPA, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-6829.
86. Hart I R, Woolley D E. Relationship between invasion and metastasis and role of proteaolytic enzymes. In: Mareel M M, Calman K C, eds. Invasion, experimental and clinical implications. Oxford: Oxford University Press, 1984: 63-78, 228-251.
87. Takeichi M. The cadherins: cell-cell adhesion molecules. Development 1988; 102: 639-655.
88. Moyer D L, Sahwi S E, McCauley D et al. In: Beller F K, Schuemacher G B R, eds. Cells of uterine fluid. Amsterdam: Elsvier, 1979: 59-71.
89. Sabourin J C, Martin A, Baruch J et al. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994; 59: 1-6.
90. Lippman M E, Dickson R B, Bats S et al. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 1986; 7: 59-70.
91. Lotzova E. Role of human circulating and tumour-infiltrating lymphocytes in cancer defense and treatment. Nat Immun Cell Growth Regul 1990; 9: 253-264.
92. Hanna W, Schnieder M. Enhancement of tumour metastasis and suppression of NK cell by beta-oestradiol treatment. J Immunol 1982; 130:974-980.
93. Poutanen M, Moncharmont B, Vihko R. 17-beta hydroxy dehydrogenase gene expression in human breast cancer cells: regulation of expression by progestin. Cancer Res 1992; 52: 290-294.
94. Tyzzer E E. Factors in production and growth of tumour metastasis. J Med Res 1913; 28: 309-332.
95. Nissen-Myer R. Adjuvant cytostatic and endocrine therapy: increased cure rate or delayed manifest disease. Commentaries on Research in Breast Disease 1979; 1: 95-109.
96. Fisher E R, Turnbull R B. The cytological demonstration and significance of tumour cells in mesenteric venous blood in patients with colorectal cancer. Surg Gynecol Obstet 1955; 100: 102-108.
97. Hansen E, Norbert Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130: 387-393.
98. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995; 346: 1334-1335.